Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | P2RY10 | O00398 | 2/20 | 0.33 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288383 | 1.00 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL18050156 | 1.00 | SLC7A5 (0.44) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL2702062 | 0.98 | SLC7A5 (0.46) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| Threonine SCHEMBL16982372 | 0.88 | SLC7A5 (0.41) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL8988392 | 0.88 | SLC1A3 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL9118329 | 0.88 | SLC1A3 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL1925209 | 0.85 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL23286474 | 0.83 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL1811512 | 0.83 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL1514131 | 0.83 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281897-A1 | Potentialization of the activation of high molecular weight prodrugs | DIATOS S.A. (FR) | 2006-12-14 | — | — | US | disclosed |
| EP-1701743-A2 | POTENTIATION OF THE ACTIVATION OF HIGH-MOLECULAR-MASS PRODRUGS | Diatos (FR) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005021043-A2 | HIGH-MOLECULAR-MASS PRODRUGS | DIATOS (FR) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281897-A1 | Potentialization of the activation of high molecular weight prodrugs | CD44, MMP12, FOLH1 | SLC7A5 523/4885SLC1A3 2811/4885SLC1A2 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.